Kymera Therapeutics (KYMR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $108.14, +1.23% vs the prior close of $106.83.
- Volume 821.00K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KYMR rises 1.2% to $108.14. Closed at $108.14, +1.23% vs the prior close of $106.83. Day range $104.62–$110.68, opened at $106.75.
KYMR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — KYMR rises 1.2% to $108.14
- Closed at $108.14, +1.23% vs the prior close of $106.83. Day range $104.62–$110.68, opened at $106.75.
- Volume was 821.00K shares, 1.1x its 50-day average of 770.10K.
- Price is -6.0% vs its 50-day average ($115.01) and +14.8% vs its 200-day average ($94.21).
- 52-week range $55.26–$130.05; today's close sits at 71% of that range, 16.8% below the 52-week high.
Oct 14, 2026 — KYMR ends flat (+0.1%) to $106.83
- Closed at $106.83, +0.14% vs the prior close of $106.68. Day range $105.58–$108.08, opened at $106.39.
- Volume was 1.03M shares, 1.4x its 50-day average of 761.55K.
- Price is -7.1% vs its 50-day average ($114.96) and +13.6% vs its 200-day average ($94.07).
- 52-week range $55.26–$130.05; today's close sits at 69% of that range, 17.9% below the 52-week high.
Oct 13, 2026 — KYMR slides 4.8% to $106.68
- Closed at $106.68, -4.82% vs the prior close of $112.08. Day range $106.52–$112.06, opened at $110.83.
- Volume was 779.10K shares, 1.0x its 50-day average of 759.30K.
- Price is -7.2% vs its 50-day average ($114.91) and +13.6% vs its 200-day average ($93.95).
- 52-week range $55.26–$130.05; today's close sits at 69% of that range, 18.0% below the 52-week high.
Oct 12, 2026 — KYMR ends flat (-0.3%) to $112.08
- Closed at $112.08, -0.28% vs the prior close of $112.40. Day range $110.52–$113.13, opened at $111.61.
- Volume was 537.50K shares, 0.7x its 50-day average of 758.78K.
- Price is -2.4% vs its 50-day average ($114.79) and +19.5% vs its 200-day average ($93.83).
- 52-week range $55.26–$130.05; today's close sits at 76% of that range, 13.8% below the 52-week high.
Oct 9, 2026 — KYMR rises 2.8% to $112.40, 3 up days in a row
- Closed at $112.40, +2.84% vs the prior close of $109.30. Day range $107.46–$115.82, opened at $109.54.
- Volume was 1.31M shares, 1.8x its 50-day average of 741.57K.
- Price is -1.9% vs its 50-day average ($114.61) and +20.0% vs its 200-day average ($93.69).
- 52-week range $55.26–$130.05; today's close sits at 76% of that range, 13.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — KYMR rises 0.9% to $109.30
- Closed at $109.30, +0.88% vs the prior close of $108.35. Day range $104.19–$110.04, opened at $106.52.
- Volume was 1.04M shares, 1.4x its 50-day average of 730.79K.
- Price is -4.5% vs its 50-day average ($114.50) and +16.8% vs its 200-day average ($93.55).
- 52-week range $55.26–$130.05; today's close sits at 72% of that range, 16.0% below the 52-week high.
Oct 7, 2026 — KYMR rises 2.2% to $108.35
- Closed at $108.35, +2.24% vs the prior close of $105.98. Day range $103.45–$108.68, opened at $104.58.
- Volume was 1.17M shares, 1.6x its 50-day average of 721.03K.
- Price is -5.3% vs its 50-day average ($114.42) and +16.0% vs its 200-day average ($93.42).
- 52-week range $55.26–$130.05; today's close sits at 71% of that range, 16.7% below the 52-week high.
Oct 6, 2026 — KYMR slides 3.5% to $105.98, a 1-month low
- Closed at $105.98, -3.52% vs the prior close of $109.85. Day range $101.75–$111.04, opened at $111.03.
- Volume was 960.70K shares, 1.4x its 50-day average of 711.29K.
- Price is -7.3% vs its 50-day average ($114.38) and +13.6% vs its 200-day average ($93.28).
- 52-week range $55.26–$130.05; today's close sits at 68% of that range, 18.5% below the 52-week high.
Oct 5, 2026 — KYMR rises 2.3% to $109.85
- Closed at $109.85, +2.29% vs the prior close of $107.39. Day range $103.33–$109.92, opened at $108.38.
- Volume was 729.70K shares, 1.0x its 50-day average of 708.40K.
- Price is -4.0% vs its 50-day average ($114.46) and +17.9% vs its 200-day average ($93.16).
- 52-week range $55.26–$130.05; today's close sits at 73% of that range, 15.5% below the 52-week high.
Oct 2, 2026 — KYMR dips 2.5% to $107.39, a 1-month low
- Closed at $107.39, -2.48% vs the prior close of $110.12. Day range $106.53–$111.23, opened at $111.23.
- Volume was 870.20K shares, 1.2x its 50-day average of 699.63K.
- Price is -6.2% vs its 50-day average ($114.47) and +15.4% vs its 200-day average ($93.03).
- 52-week range $54.35–$130.05; today's close sits at 70% of that range, 17.4% below the 52-week high.
KYMR latest news & SEC filings
Every SEC filing by or about KYMR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mainolfi Nello converted options/RSUs into 30,000 shares at $2.08 (≈$62.40K) on Oct 1, 2026; now holds 696,568
- Mainolfi Nello sold 3,525 shares at $111.44 (≈$392.83K) on Oct 1, 2026; now holds 693,043
- Mainolfi Nello sold 5,506 shares at $112.42 (≈$618.98K) on Oct 1, 2026; now holds 687,537
- Mainolfi Nello sold 4,876 shares at $113.24 (≈$552.16K) on Oct 1, 2026; now holds 682,661
- Mainolfi Nello sold 7,601 shares at $114.43 (≈$869.78K) on Oct 1, 2026; now holds 675,060
- Mainolfi Nello sold 8,230 shares at $115.40 (≈$949.74K) on Oct 1, 2026; now holds 666,830
- …plus 1 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 4, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Adams Brian sold 1,209 shares at $115.55 (≈$139.70K) on Sep 4, 2026
- Adams Brian sold 3,025 shares at $116.81 (≈$353.35K) on Sep 4, 2026
- Adams Brian sold 2,137 shares at $117.57 (≈$251.25K) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $65.00M (prior year $11.48M) (+466.4% vs Jun 30, 2025)
- Net income: -$61.21M (prior year -$76.61M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.62 (prior year -$0.95) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 27, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 26, 2026 · SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 25, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jun 24, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade KYMR
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 26, 2026, Jan 13, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.91% (largest 5.4%).
- Liquidity: about 915.83K shares (≈$99.04M) trade per day on average.
- 52-week position: $108.14 vs a range of $55.26–$130.05 (71% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Brian Adams sold 1,209 shares on Sep 4, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jul 27, 2026.
- Share count: 83.15M shares outstanding (Jul 31, 2026), +16.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
KYMR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 106.75 | 110.68 | 104.62 | 108.14 | 821.00K |
| Oct 14, 2026 | 106.39 | 108.08 | 105.58 | 106.83 | 1.03M |
| Oct 13, 2026 | 110.83 | 112.06 | 106.52 | 106.68 | 779.10K |
| Oct 12, 2026 | 111.61 | 113.13 | 110.52 | 112.08 | 537.50K |
| Oct 9, 2026 | 109.54 | 115.82 | 107.46 | 112.40 | 1.31M |
| Oct 8, 2026 | 106.52 | 110.04 | 104.19 | 109.30 | 1.04M |
| Oct 7, 2026 | 104.58 | 108.68 | 103.45 | 108.35 | 1.17M |
| Oct 6, 2026 | 111.03 | 111.04 | 101.75 | 105.98 | 960.70K |
| Oct 5, 2026 | 108.38 | 109.92 | 103.33 | 109.85 | 729.70K |
| Oct 2, 2026 | 111.23 | 111.23 | 106.53 | 107.39 | 870.20K |
| Oct 1, 2026 | 111.79 | 116.20 | 109.41 | 110.12 | 1.05M |
| Sep 30, 2026 | 110.74 | 115.69 | 108.03 | 111.79 | 1.02M |
| Sep 29, 2026 | 110.54 | 111.92 | 108.97 | 110.51 | 448.20K |
| Sep 28, 2026 | 111.95 | 113.60 | 110.51 | 112.00 | 723.70K |
| Sep 25, 2026 | 115.99 | 116.20 | 111.42 | 111.95 | 698.40K |
| Sep 24, 2026 | 115.28 | 116.40 | 111.36 | 115.81 | 841.70K |
| Sep 23, 2026 | 121.29 | 123.00 | 112.91 | 115.47 | 969.60K |
| Sep 22, 2026 | 119.03 | 122.37 | 117.88 | 122.06 | 779.40K |
| Sep 21, 2026 | 117.75 | 119.53 | 116.61 | 117.67 | 636.90K |
| Sep 18, 2026 | 119.06 | 119.06 | 116.36 | 117.75 | 1.90M |
About Kymera Therapeutics
Kymera Therapeutics (KYMR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WATERTOWN, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1815442.
KYMR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jun 25, 2026 |
| Jeffrey W. Albers | Director | Jun 25, 2026 |
| Bros. Advisors Lp Baker | Director | Jun 25, 2026 |
| Felix Baker | Director | Jun 25, 2026 |
| Julian Baker | Director | Jun 25, 2026 |
| Value Fund Ii Lp Biotechnology | See Remarks and Footnotes | Jun 26, 2026 |
| Value Fund L P Biotechnology | See Remarks and Footnotes | Jun 26, 2026 |
| Gp Holdings Llc Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| I Gp Llc Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| Ii Gp Llc Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| Inc/Il Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| Partners L P/Il Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| Partners Os Ltd. Bvf | See Remarks and Footnotes | Jun 26, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jun 25, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jun 25, 2026 |
| Value Trading Fund Os Lp Biotechnology | See Remarks and Footnotes | Jun 26, 2026 |
| Bruce Booth | Director | Jul 2, 2026 |
| Pamela Esposito | Director | Jun 25, 2026 |
| Gorjan Hrustanovic | Director | Jun 25, 2026 |
| Mark N Lampert | See Remarks and Footnotes | Jun 26, 2026 |
| John Maraganore | Director | Jun 25, 2026 |
| Nello Mainolfi | Chief Executive Officer | Jul 7, 2026 |
| Elena Ridloff | Director | Jun 25, 2026 |
| Victor Sandor | Director | Jun 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Brian Adams | Chief Legal Officer | Sep 4, 2026 |
| Jeremy G Chadwick | Chief Operating Officer | May 27, 2026 |
| Jared Gollob | Chief Medical Officer | Mar 4, 2026 |
| Noah Goodman | Chief Business Officer | Jul 2, 2026 |
| Bruce N. Jacobs | Chief Financial Officer | Jul 2, 2026 |
| Nello Mainolfi | Chief Executive Officer | Jul 7, 2026 |
| Terence Rooney | Chief Medical Officer | Jul 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Brian Adams | Sale | 1,209 | $115.55 |
| Sep 4, 2026 | Brian Adams | Sale | 3,025 | $116.81 |
| Sep 4, 2026 | Brian Adams | Sale | 2,137 | $117.57 |
| Jul 7, 2026 | Nello Mainolfi | Sale | 50,000 | $119.00 |
| Jul 1, 2026 | Noah Goodman | Sale | 3,389 | $114.29 |
| Jul 1, 2026 | Nello Mainolfi | Sale | 1,883 | $112.80 |
| Jul 1, 2026 | Nello Mainolfi | Sale | 6,626 | $113.98 |
| Jul 1, 2026 | Nello Mainolfi | Sale | 44,050 | $115.69 |
| Jul 1, 2026 | Nello Mainolfi | Sale | 24,105 | $114.96 |
| Jul 1, 2026 | Nello Mainolfi | Sale | 3,336 | $116.56 |
| Jun 30, 2026 | Bruce N. Jacobs | Sale | 1,100 | $112.79 |
| Jun 30, 2026 | Bruce N. Jacobs | Sale | 4,110 | $114.19 |
| Jun 30, 2026 | Bruce N. Jacobs | Sale | 51,375 | $114.77 |
| Jun 30, 2026 | Bruce N. Jacobs | Sale | 1,700 | $111.57 |
| Jun 30, 2026 | Bruce N. Jacobs | Sale | 1,500 | $110.54 |
KYMR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $39.21M | $-311.35M | -3.69 | $-232.89M |
| Dec 31, 2024 | $47.07M | $-223.86M | -2.98 | $-194.50M |
| Dec 31, 2023 | $78.59M | $-146.96M | -2.52 | $-102.83M |
| Dec 31, 2022 | $46.83M | $-154.81M | -2.87 | $-153.09M |
| Dec 31, 2021 | $72.83M | $-100.22M | -2.09 | $-128.95M |
Latest balance sheet: total assets $1.65B, total liabilities $136.19M, cash $124.48M (as of Jun 30, 2026).
KYMR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $105.48 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $81.07 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $95.03 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $74.13 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $59.91 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $37.68 |
| May 9, 2025 | 8-K Item 2.02 (results) | $30.07 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $30.25 |
| Jan 14, 2025 | 8-K Item 2.02 (results) | $40.12 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $46.17 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on KYMR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.